Key result
Review evaluates apixaban benefit-risk profiles when co-administered with CYP3A4 and P-gp inhibitors or inducers.
Why the study?
Clinicians need to consider the benefit-risk profile of individual anticoagulants when balancing the need for anticoagulation, including risks in patients with comorbidities and potential drug-drug interactions.
What is the benefit-risk profile of apixaban when co-administered with CYP3A4 and/or P-glycoprotein interacting medications?
What is the benefit-risk profile of apixaban when co-administered with CYP3A4 and/or P-glycoprotein interacting medications?
This narrative review summarizes the clinical implications and benefit-risk profile of co-administering apixaban with CYP3A4 and P-gp interacting medications, including in special populations like cancer and COVID-19.
Answers are grounded in this paper and cite their sources.
Caution advised with apixaban plus CYP3A4/P-gp interactors; leaves open need for prospective interaction studies.
With many available data sources, clinicians need to consider the benefit-risk profile of individual anticoagulants when balancing the need for anticoagulation, including evaluating the risks in patients with comorbidities and potential drug-drug interactions. This narrative review presents clinical data across multiple phases of drug development for the use of apixaban, a selective factor Xa inhibitor, when taken concomitantly with other agents, and evaluates the benefit-risk profile of apixaban with these interacting medications. Key subgroup analyses from the phase 3 ARISTOTLE trial (NCT00412984) are presented using data from patients who received either concomitant inhibitors or inducers of cytochrome P450 3A4 and/or P‑glycoprotein. We also review the available evidence for the use of apixaban in patients with cancer-associated thromboembolism, as well as the use of apixaban in patients with COVID-19.
No takes yet. Share an insight, caveat, or question.
Favatella et al. (2024) conducted a review in Patients requiring anticoagulation with comorbidities and potential drug-drug interactions. Apixaban co-administered with interacting medications was evaluated. This narrative review evaluates the benefit-risk profile of apixaban when co-administered with key interacting medications, including CYP3A4 and P-glycoprotein inhibitors or inducers.
Synapse has enriched 10 related papers. Consider them for comparative context: